The recent clinical trial published in JAMA Oncology revealed that a combination treatment of a PARP inhibitor and chemotherapy did not improve survival in glioblastoma patients compared to placebo.
Priya Kumthekar, MD, emphasized the urgency of discovering more effective therapies for glioblastoma. Despite advancements, the disease remains highly resistant to treatment, showcasing the need for further research.
Current average survival for glioblastoma patients remains disappointingly low at eight months, highlighting the critical importance of developing novel treatment strategies to extend patient life expectancy.
The study found that while veliparib paired with temozolomide showed promise in prior research, the large-scale trial did not yield the expected improvements in patient outcomes.
Collection
[
|
...
]